Dividend
-
-
-
-
-
-
-
AMGEN TAKES ACTION WITH THE U.S. GOVERNMENT TO LOWER THE COST OF MEDICINES FOR AMERICAN PATIENTS
-
-
-
-
-
-
-
Amgen's Repatha reduces heart attack risk by 25% in major study
-
-
-
-
-
-
-
FDA approves TEZSPIRE for chronic rhinosinusitis with nasal polyps
-
-
-
-
-
-
-
Amgen plans $650 million manufacturing expansion, creating 750 jobs
-
-
-
-
-
-
-
AMGEN INVESTING MORE THAN HALF A BILLION DOLLARS IN NEW, STATE-OF-THE-ART CENTER FOR SCIENCE AND INNOVATION AT U.S. GLOBAL HEADQUARTERS
-
-
-
-
-
-
-
AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR BEMARITUZUMAB IN FIBROBLAST GROWTH FACTOR RECEPTOR 2b (FGFR2b) POSITIVE FIRST-LINE GASTRIC CANCER
-
-
-
-
-
-
-
Amgen (AMGN) confirms $900M Ohio manufacturing expansion
-
436,668 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

